| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
17,070,000 |
| Market
Cap: |
92.01(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.39 - $5.39 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company. Co. is developing a modular peptide-nucleic acid antisense oligo (PATrOL™) platform to address genetic diseases. Co.'s programs are: NT0100, which is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the Huntington's disease messenger ribonucleic acid; NT0200, which is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the myotonic dystrophy type 1 disease messenger ribonucleic acid; and NT-0300, which is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
61,076 |
61,076 |
| Total Buy Value |
$0 |
$0 |
$59,732 |
$59,732 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
489,520 |
489,520 |
| Total Sell Value |
$0 |
$0 |
$712,352 |
$712,352 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
6 |
6 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hirschman Orin |
Director |
– • – |
2014-04-30 |
5 |
GD |
$0.00 |
$0 |
I/I |
23,300 |
1,673,948 |
|
- |
|
| Riedhammer Thomas M |
Director |
– • – |
2014-04-10 |
4 |
B |
$10.36 |
$11,396 |
D/D |
1,100 |
117,767 |
2.39 |
- |
|
| Greenstein Ira A |
Director |
– • – |
2014-04-09 |
4 |
B |
$10.20 |
$25,500 |
D/D |
2,500 |
455,496 |
2.39 |
- |
|
| Almenoff June Sherie |
Director |
– • – |
2014-04-08 |
4 |
B |
$10.25 |
$56,375 |
D/D |
5,500 |
122,166 |
2.39 |
- |
|
| Hirschman Orin |
Director |
– • • |
2013-06-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
83,000 |
|
- |
|
| Hirschman Orin |
Director |
– • • |
2013-06-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,490,059 |
|
- |
|
| Greenstein Ira A |
Chairman of the BoardOfficer |
• • – |
2013-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
266,769 |
|
- |
|
| Taraporewala Irach B. |
CEO & PresidentOfficer |
• – – |
2013-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,095 |
|
- |
|
| Backenroth Samuel |
CEO & VP of Bus. DevelopmentOf |
• – – |
2013-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,699 |
|
- |
|
84 Records found
|
|
Page 4 of 4 |
|
|
